NousCom presents at the 1ST Meeting of the European Hereditary Tumour Group (EHTG)
Palma, Mallorca Abstract Title: Development of cell based immunity based on multiple epitopes: Lessons from prophylactic genetic vaccines.
Palma, Mallorca Abstract Title: Development of cell based immunity based on multiple epitopes: Lessons from prophylactic genetic vaccines.
Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.
